TNDM Stock Recent News

The latest addition to TNDM's pump platform portfolio, Tandem Mobi, is leading the way in creating a whole new category of devices for insulin therapy.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today announced the planned release of version 2.8.2 of its Apple iOS t:connect mobile app in the United States on August 20, 2024 to correct an issue described in a March 2024 recall that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to see following the release of version 2.7.1 of the.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) today provided an update on the March 2024 recall of its Apple iOS t:connect mobile app in the United States relating to an issue that can cause rapid depletion of a user's t:slim X2 insulin pump battery. This battery depletion can result in the pump shutting down sooner than expected, which some customers have continued to experience following the release of version 2.7.1 of the app in March. Notices were emailed to impacted.

NEW YORK, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Tandem Diabetes Care, Inc. (NASDAQ: TNDM) on behalf of long-term stockholders following a class action complaint that was filed against Tandem on September 8, 2023 with a Class Period from August 3, 2022 to November 2, 2022. Our investigation concerns whether the board of directors of Tandem have breached their fiduciary duties to the company.

Tandem Diabetes' (TNDM) top and bottom lines outpace estimates in the second quarter, backed by the demand for both t:slim X2 and the newly launched Tandem Mobi.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Susan Morrison - Executive Vice President and Chief Administrative Officer. John Sheridan - President and Chief Executive Officer Mark Novara - Executive Vice President and Chief Commercial Officer Leigh Vosseller - Executive Vice President and Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets.

While the top- and bottom-line numbers for Tandem Diabetes Care (TNDM) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.30 per share a year ago.

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2024 and increased sales guidance for the year ending December 31, 2024. Second Quarter 2024 Highlights Worldwide GAAP sales increased 13 percent to $221.9 million compared to second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to $221.8 million compared to second quarter 2023. More.

Tandem Diabetes Care, Inc. TNDM announced the latest real-world insights from a user satisfaction survey on their Tandem Mobi system during the 84th Scientific Sessions of the American Diabetes Association (“ADA”) in Orlando, FL. Data from the survey demonstrated that Tandem Mobi helps improve the quality of life for patients with type 1 diabetes.